13 minute read
Oct. 20, 2023
Vorasidenib: A Brain-Penetrant mIDH1/2 Inhibitor with Stunning Efficacy in Glioma
vorasidenib
oral first-in-class dual IDH1/IDH2 inhibitor efficacy in Ph. III for mIDH grade 2 gliomas, 40 mg QD from SBDD of prior mIDH inhibitor N. Engl. J. Med., June 4, 2023 Agios, Cambridge; Servier, Boston, MA
Author:
Editor: